Patent ID: 11858963
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 4:
5. The immunogenic composition of claim 1, wherein the modified PCV2 ORF2 protein containing the at least one mutation in the BC loop is expressed in a baculovirus expression system in a higher amount, or in a higher amount by at least a factor 2, or in a higher amount by at least a factor 3, or in a higher amount by at least a factor 5, or in a higher amount by at least a factor 8 compared to a PCV2 ORF2 protein that does not contain such mutation, and/or the modified PCV2 ORF2 protein containing the at least one mutation in the BC loop is expressed in a higher amount in a baculovirus expression system compared to the modified PCV2 ORF2 protein that does not contain such mutation and/or wherein the modified PCV2 ORF2 protein that does not contain such mutation is a wild type PCV2 ORF2 protein.